BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 31734021)

  • 1. Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold.
    Qin M; Cao Q; Wu X; Liu C; Zheng S; Xie H; Tian Y; Xie J; Zhao Y; Hou Y; Zhang X; Xu B; Zhang H; Wang X
    Eur J Med Chem; 2020 Jan; 186():111856. PubMed ID: 31734021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Yang Y; Wang K; Chen H; Feng Z
    Eur J Med Chem; 2021 Feb; 211():113001. PubMed ID: 33272783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of [1,2,4]Triazolo[4,3- a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
    Qin M; Cao Q; Zheng S; Tian Y; Zhang H; Xie J; Xie H; Liu Y; Zhao Y; Gong P
    J Med Chem; 2019 May; 62(9):4703-4715. PubMed ID: 30964291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
    Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
    Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
    Huang X; Chen H; Dai X; Xu M; Wang K; Feng Z
    Bioorg Med Chem Lett; 2021 Nov; 52():128403. PubMed ID: 34610423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.
    Cheng B; Ren Y; Niu X; Wang W; Wang S; Tu Y; Liu S; Wang J; Yang D; Liao G; Chen J
    J Med Chem; 2020 Aug; 63(15):8338-8358. PubMed ID: 32667799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
    Qin M; Meng Y; Yang H; Liu L; Zhang H; Wang S; Liu C; Wu X; Wu D; Tian Y; Hou Y; Zhao Y; Liu Y; Xu C; Wang L
    J Med Chem; 2021 May; 64(9):5519-5534. PubMed ID: 33938739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
    Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
    Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Wang Y; Kun Huang ; Gao Y; Yuan D; Ling L; Liu J; Wu S; Chen R; Li H; Xiong Y; Liu H; Ma J
    Eur J Med Chem; 2022 Feb; 229():113998. PubMed ID: 34839997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
    Wu Y; Zhang Y; Guo Y; Pan Z; Zhong S; Jin X; Zhuang W; Chen S; Gao J; Huang W; Dong X; Che J
    Eur J Med Chem; 2021 Nov; 223():113637. PubMed ID: 34147746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo[4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
    Dai X; Wang K; Chen H; Huang X; Feng Z
    Bioorg Chem; 2021 Sep; 114():105034. PubMed ID: 34116264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction.
    Fang L; Tian J; Zhang K; Zhang X; Liu Y; Cheng Z; Zhou J; Zhang H
    Bioorg Med Chem; 2021 Sep; 46():116370. PubMed ID: 34481337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
    Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
    Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
    Wang T; Cai S; Wang M; Zhang W; Zhang K; Chen D; Li Z; Jiang S
    J Med Chem; 2021 Jun; 64(11):7390-7403. PubMed ID: 34056906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1.
    Cheng B; Ren Y; Cao H; Chen J
    Eur J Med Chem; 2020 Aug; 199():112377. PubMed ID: 32388281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment.
    Cao H; Cheng B; Liu T; Chen J
    Biochem Pharmacol; 2021 Jun; 188():114522. PubMed ID: 33741334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
    Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
    J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.
    Boohaker RJ; Sambandam V; Segura I; Miller J; Suto M; Xu B
    Cancer Lett; 2018 Oct; 434():11-21. PubMed ID: 29920293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction.
    Muszak D; Surmiak E; Plewka J; Magiera-Mularz K; Kocik-Krol J; Musielak B; Sala D; Kitel R; Stec M; Weglarczyk K; Siedlar M; Dömling A; Skalniak L; Holak TA
    J Med Chem; 2021 Aug; 64(15):11614-11636. PubMed ID: 34313116
    [TBL] [Abstract]